AAD  Vol.3 No.3 , September 2014
Rivastigmine Restores 5-HT1A Receptor Levels in the Hippocampus of Olfactory Bulbectomized Mice
Abstract: Rivastigmine, a dual acetylcholinesterase and butyrylcholinesterase inhibitor, is used for symptomatic treatment of patients with mild to moderately severe dementia in Alzheimer’s disease (AD) patients. In the present study, we found that 5-HT1A receptor (5-HT1AR) is downregulated, whereas 5-HT2A receptor (5-HT2AR) is upregulated in the hippocampal dentate gyrus (DG) and CA1 region by olfactory bulbectomy (OBX) in mice. Furthermore, chronic treatment with rivastigmine (1.0 mg/kg) for 2 weeks starting 2 weeks after OBX operation restored the decreased 5-HT1AR and the increased 5-HT2AR levels. To determine whether cholinergic receptor stimulation by rivastigmine is involved in the rivastigmine-induced regulation of 5-HTR levels, we treated the mice with mecamylamine (2.5 mg/kg), or atropine (5.0 mg/kg) with rivastigmine (1.0 mg/kg) once a day for 2 weeks. Notably, the rivastigmine-induced 5-HT1AR upregulation was eliminated by mecamylamine but not by atropine treatments. On the other hand, the restored 5-HT2AR level by rivastigmine was not affected by either mecamylamine or atropine. Treatment with 8-OH-DPAT, a selective 5-HT1AR agonist improved the decreased 5-HT1AR and the increased 5-HT2AR levels in OBX mice. On the other hand, treatment with TCB-2, a potent 5-HT2AR agonist had no effects on the 5-HT1AR and 5-HT2AR dysregulation in OBX mice. Taken together, nicotinic acetylcholine receptor (nAChR) stimulation mediates rivastigmine-induced upregulation of 5-HT1AR. Therefore, we speculate that the increased ACh levels by rivastigmine can stimulate nAChR located on serotonergic nerve terminals and stimulate 5-HT1AR by the enhanced 5-HT release in the hippocampus. The 5-HT1AR stimulation likely mediates the improvement of 5-HT1AR levels as auto-receptor in OBX hippocampus.
Cite this paper: Islam, M. , Moriguchi, S. , Tagashira, H. and Fukunaga, K. (2014) Rivastigmine Restores 5-HT1A Receptor Levels in the Hippocampus of Olfactory Bulbectomized Mice. Advances in Alzheimer's Disease, 3, 128-136. doi: 10.4236/aad.2014.33012.

[1]   Thomsen, M.S., Hansen, H.H., Timmerman, D.B. and Mikkelsen, J.D. (2010) Cognitive Improvement by Activation of Alpha 7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology. Current Pharmaceutical Design, 16, 323-343.

[2]   Richardson-Jones, J.W., Craige, C.P., Guiard, B.P., Stephen, A., Metzqer, K.L., Kung, H.F., Gardier, A.M., Drarovsky, A., David, D.J., Deck, S.G., Hen, R. and Leonardo, E.D. (2010) 5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to Antidepressants. Neuron, 65, 40-51.

[3]   Berumen, L.C., Rodríquez, A., Miledi, R. and García-Alcour, G. (2012) Serotonin Receptors in Hippocampus. Scientific World Journal, 2012, Article ID: 823493.

[4]   Xu, T. and Pandey, S.C. (2000) Cellular Localization of Serotonin2A (5-HT2A) Receptors in Rat Brain. Brain Research Bulletin, 51,499-505.

[5]   Bombardi, C. and Di Giovanni, G. (2013) Functional Anatomy of 5-HT2A Receptors in the Amygdale and Hippocampal Complex: Relevance to Memory Functions. Experimental Brain Research, 230, 427-439.

[6]   Sur, C., Betz, H. and Schloss, P. (1996) Immunocytochemical Detection of the Serotonin Transporter in Rat Brain. Neuroscience, 73, 217-231.

[7]   Tao-Cheng, J.H. and Zhou, F.C. (1999) Differential Polarization of Serotonin Transporters in Axons versus So- ma-Dendrites: An Immunogold Electron Microscope Study. Neuroscience, 94, 821-830.

[8]   Blakely, R.D., De Felice, L.J. and Hartzell, H.C. (1994) Physiology of Norepinephrine and Serotonin Receptors. The Journal of Experimental Biology, 196, 1263-281.

[9]   Breuer, M.E., Groenink, L., Oosting, R.S., Buerger. E., Korte, M., Ferger, B. and Olivier, B. (2009) Antidepressant Effects of Pramipexole, a DopamineD3/D2 Receptor Agonist, and 7-OH-DPAT, a Dopamine D3 Receptor Agonist, in Olfactory Bulbectomized Rats. European Journal of Pharmacology, 616, 134-140.

[10]   Hsuchou, H., Ho, Y.J., Shui, H.A., Tai, M.Y., Chen, K.H. and Tsai, Y.F. (2002) Effects of Incisor-Cutting on Muricidal Behavior Induced by Olfactory Bulbectomy in Rats. Physiology & Behavior, 76, 669-675.

[11]   Hozumi, S., Nakagawasai, O., Tan-No, K., Niijima, F., Murata, A., Arai, Y., Yasuhara, H. and Tadano, T. (2003) Characteristics of Changes in Cholinergic Function and Impairment of Learning-Memory Related Behavior Induced by Olfactory Bulbectomy. Behavioral Brain Research, 138, 9-15.

[12]   Aleksandrova, I.Y., Kuvichkin, V.V., Kashparov, I.A., Medvinskaya, N.I., Nesterova, I.V., Lunin, S.M., Samokhin, A.N. and Bobkova, N.V. (2004) Increased Level of β-Amyloid in the Brain of Bulbectomized Mice. Biochemistry (Moscow), 69, 176-180.

[13]   Han, F., Shioda, N., Moriguchi, S., Yamamoto, Y., Raie, A.A., Yamaguchi, Y., Hino, M. and Fukunaga, K. (2008) Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) Treatment Rescues Olfactory Bulbectomy- Induced Memory Impairment by Activation of Ca2+/Calmodulin Kinase II and Preotin Kinase C in Mouse Hippocampus. The Journal of Pharmacology and Experimental Therapeutics, 326, 127-134.

[14]   Shioda, N., Yamamoto, Y., Han, F., Moriguchi, S., Yamaguchi, Y., Hino, M. and Fukunaga, K. (2010) A Novel Cognitive Enhancer, ASET1446/ST101, Promotes Hippocampal Neurogenesis and Ameliorates Depressive Behavior in Olfactory Bulbectomized Mice. Journal of Pharmacology and Experimental Therapeutics, 333, 43-50.

[15]   Neckers, L.M., Zarrow, M.X., Myers, M.M. and Denenberg, V.H. (1975) Influence of Olfactory Bulbectomy and the Serotonergic System upon Intermale Aggression and Maternal Behavior in the Mouse. Pharmacology Biochemistry and Behavior, 3, 545-550.

[16]   Watanabe, A., Tohyama, Y., Nguyen, K.Q., Hasegawa, S., Debonnel, G. and Diksic, M. (2003) Regional Brain Serotonin Synthesis Is Increased in the Olfactory Rat Model of Depression: An Autoradiographic Study. Journal of Neurochemistry, 85, 469-475.

[17]   Cross, A.J., Crow, T.J., Ferrier, I.N., Johnson, J.A., Bloom, S.R. and Corsellis, J.A. (1984) Serotonin Receptor Changes in Dementia of the Alzhemier Type. Journal of Neurochemistry, 43, 1574-1581.

[18]   Mann, D.M. and Yates, P.O. (1983) Serotonin Nerve Cells in Alzheimer’s Disease. Journal of Neurology, Neurosurgery & Psychiatry, 46, 96-98.

[19]   Lai, M.K., Tsang, S.W., Esiri, M.M., Francis, P.T., Wong, P.T. and Chen, C.P. (2011) Differential Involvement of Hippocampal Serotonin1A Receptors and Re-Uptake Sites in Non-Cognitive Behaviors of Alzheimer’s Disease. Psychopharmacology, 213, 431-439.

[20]   Wilkinson, D.G., Francis, P.T., Schwam, E. and Payne-Parrish, J. (2004) Cholinesterase Inhibitors Used in the Treatment of Alzheimer’s Disease: The Relationship between Pharmacological Effects and Clinical Efficacy. Drugs & Aging, 21, 453-478.

[21]   Mowla, A., Mosavinasab, M., Haghshenas, H. and Borhani Haghighi, A. (2007) Does Serotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer’s Dementia? A Double-Blind, Placebo-Controlled Clinical Trial. Journal of Clinical Psychopharmacology, 27, 484-487.

[22]   McDermott, C.L. and Gray, S.L. (2012) Cholinesterase Inhibitor Adjunctive Therapy for Cognitive Impairment and Depressive Symptoms in Older Adults with Depression. Annals of Pharmacotherapy, 46, 599-605.

[23]   Spalletta, G., Gianni, W., Giubilei, F., Casini, A.R., Sancesario, G., Caltaqirone, C. and Cravello, L. (2013) Rivastigmine Patch Ameliorates Depression in Mild AD: Preliminary Evidence from a 6-Month Open-Label Observational Study. Alzheimer Disease & Association Disorder, 27, 289-291.

[24]   Moriguchi, S., Tagashira, H., Sasaki, Y., Yeh, J.Z., Sakagami, H., Narahashi, T. and Fukunaga, K. (2014) CaMKII Activity Is Essential for Improvement of Memory-Related Behaviors by Chronic Rivastigmine Treatment. Journal of Neurochemistry, 128, 927-937.

[25]   Islam, M.R., Moriguchi, S., Tagashira, H. and Fukunaga, K. (2014) Rivastigmine Improves Hippocampal Neurogenesis and Depression-Like Behaviors via 5-HT1A Receptor Stimulation in Olfactory Bulbectomized Mice. Neuroscience, 272, 116-130.

[26]   Singer, S., Rossi, S., Verzosa, S., Hashim, A., Konow, R., Cooper, T., Serchen, H. and Lajtha, A. (2004) Nicotine-Induced Changes in Neurotransmitter Levels in Brain Areas Associated with Cognitive Function. Neurochemical Research, 29, 1779-1792.

[27]   Jarosik, J., Legutko, B., Unsicker, K. and von Bohlen Und Halbach, O. (2007) Antidepressant-Mediated Reversal of Abnormal Behavior and Neurodegenaration in Mice Following Olfactory Bulbectomy. Experimental Neurology, 204, 20-28.

[28]   Westlind, A., Grynfarb, M., Hedlund, B., Bartfai, T. and Fuxe, K. (1981) Muscarinic Supersentivity Induced by Septal Lesion or Chronic Atropine Treatment. Brain Research, 225, 131-141.

[29]   Chen, Y., Shohami, E., Bass, R. and Weinstock, M. (1998) Cerebro-Protective Effects of ENA-713, a Novel Acetylcholinesterase Inhibitor, in Closed Head Injury in the Rat. Brain Research, 784, 18-24.

[30]   Rao, T., Correa, L.D., Reid, R.T. and Lioyd, G.K. (1996) Evaluation of Anti-Nociceptive Effects of Neuronal Nicotinic Acetylcholine Receptor (nAChR) Ligands in the Rat Tail-Flick Assay. Neuropharmacology, 35, 393-405.

[31]   Kenny, P.J., File, S.E. and Neal, M.J. (2000) Evidence for a Complex Influence of Nicotinic Acetylcholine Receptors on Hippocampal Serotonin Release. Journal of Neurochemistry, 75, 2409-2414.

[32]   De la Garza II, R. and Yoon, J.H. (2011) Evaluation of the Effects of Rivastigmine on Cigarette Smoking by Methamphetamine-Dependent Volunteers. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35, 1827-1830.

[33]   Kenny, P.J., Cheeta, S. and File, S.E. (2000) The Anxiogenic Effects of Nicotine in the Dorsal Hippocampus Are Mediated by 5-HT1A and Not Muscarinic M1 Receptors. Neuropharmacology, 39, 300-307.

[34]   Reid, R.T. and Sabbagh, M.N. (2008) Effects of Cholinesterase Inhibitors on Rat Nicotinic Receptors Levels in Vivo and in Vitro. Journal of Neural Transmission, 115, 1437-1444.

[35]   Nizri, E., Irony-Tur-Sinai, M., Faranesh, N., Lavon, I., Lavi, E., Weinstock, M. and Benner, T. (2008) Suppression of Neuroinflammation and Immunomodulation by the Acetylcholinesterase Inhibitor Rivastigmine. Journal of Neuroimmunology, 203, 12-22.

[36]   Sato, H., Skelin, I. and Diksic, M. (2010) Chronic Busiprone Treatment Decreases 5-HT1B Receptor Densities and the Serotonin Transporter but Increases the Density of 5-HT2A Receptors in the Bulbectomied Rat Model of Depression: An Autoradiographic Study. Brain Research, 1345, 28-44.

[37]   Kato, K., Awasaki, T. and Ito, K. (2009) Neuronal Programmed Cell Death Induces Glial Cell Division in the Adult Drosophila Brain. Development, 136, 51-59.